(Q40180565)

18 September 2017

title

Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates (English)

1 reference

18 September 2017

0 references

rabies virus

1 reference

5

1 reference

18 September 2017

Charles Edward Rupprecht

11

object named as

Charles E Rupprecht

1 reference

18 September 2017

3

William Weldon

1 reference

18 September 2017

2

Cathleen Hanlon

1 reference

18 September 2017

Susan E Sloan

1

1 reference

18 September 2017

Michael Niezgoda

4

1 reference

18 September 2017

Josh Self

6

1 reference

18 September 2017

Kirk J Rowley

7

1 reference

18 September 2017

Robert B Mandell

8

1 reference

18 September 2017

Gregory J Babcock

9

1 reference

18 September 2017

William D Thomas

10

1 reference

18 September 2017

Donna M Ambrosino

12

1 reference

18 September 2017

language of work or name

English

0 references

publication date

29 December 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

25

1 reference

18 September 2017

issue

15

1 reference

18 September 2017

page(s)

2800-2810

1 reference

Additional reports of failure to respond to treatment after rabies exposure in Thailand

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Failure of postexposure treatment of rabies in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Failure of rabies postexposure treatment in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Glycoprotein of nonpathogenic rabies viruses is a key determinant of human cell apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Advances in surface plasmon resonance biosensor analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

The incurable wound revisited: progress in human rabies prevention?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Efficacy of rabies biologics against new lyssaviruses from Eurasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Case report: isolation of a European bat lyssavirus type 2a from a fatal human case of rabies encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Mechanisms of rabies virus neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.031

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.12.031

1 reference

18 September 2017

1 reference